FIELD: biotechnology.
SUBSTANCE: present invention relates to a method of improving procoagulant properties of tissue factor (TF) expressed in eukaryotic cells, and can be used in medicine. Modified tissue factor bearing microvesicle produced in accordance with present invention can be used as procoagulant agent for treating bleeding, wound healing and stimulating angiogenesis in tissues.
EFFECT: invention improves procoagulant properties of tissue factor due to that obtained TF bearing microvesicle is generated from lipid membranes or their fragments of eukaryotic cells, in which tissue factor is expressed, as well as additional additive of negatively charged phospholipid.
18 cl, 16 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MICROVESICLES DERIVED FROM RECOMBINANT YEAST HAVING HAEMOSTATIC ACTIVITIES AND USE THEREOF | 2007 |
|
RU2492184C2 |
| NEW THROMBOMODULINE FUSION PROTEINS PROVIDING DIRECTIONAL TRANSFER TO TISSUE FACTOR AS ANTICOAGULANTS | 2003 |
|
RU2320366C2 |
| GLA DOMAINS AS THERAPEUTIC AGENTS | 2014 |
|
RU2705786C2 |
| MODIFIED FACTOR VII-BASED POLYPEPTIDES AND THEREOF APPLICATION | 2008 |
|
RU2571931C2 |
| VESICLES CONTAINING PTEN INHIBITOR AND THEIR USE | 2019 |
|
RU2800729C2 |
| GLA DOMAINS AS TARGETING AGENTS | 2014 |
|
RU2731507C1 |
| METHOD OF ESTIMATION OF THE DEGREE OF FORMATION OF ERYTHROCYTE VESICLES | 2017 |
|
RU2667125C1 |
| KIT FOR MEASUREMENT OF THROMBIN FORMATION IN SAMPLED PATIENT'S BLOOD OR PLASMA | 2005 |
|
RU2360970C2 |
| GLA DOMAINS AS TARGETING AGENTS | 2014 |
|
RU2711091C2 |
| COMPOSITIONS CONTAINING CELL VESICLES AND USE THEREOF | 2019 |
|
RU2824136C2 |
